Literature DB >> 16784654

[Clinicopathological significance of aberrant methylation of the fragile histidine triad gene in patients with hepatocellular carcinoma].

Yun Sun1, Xiao-ping Geng, Li-xin Zhu, Qi-ru Xiong, Ye-ben Qian, Gui-yin Dong, Xiao-ming Li.   

Abstract

OBJECTIVE: To investigate the aberrant methylation of fragile histidine triad (FHIT) gene and to explore possible relationship between the aberrant methylation of FHIT and clinicopathological features in hepatocellular carcinoma (HCC).
METHODS: The hypermethylation of FHIT was detected by the methylation specific PCR (MSP) method in 45 patients with HCC (tumoral and nontumoral tissue), 14 cases of normal livers and 4 HCC cell lines (SK-Hep-1, Hep-G2, Hep-3B and Huh7). The correlation of FHIT methylation and clinicopathological features was analyzed.
RESULTS: The frequencies of hypermethylation of FHIT in tumoral and nontumoral tissue, normal liver and cell lines were 71.1%, 64.4%, 14.3% and 75.0%, respectively. A significant relation between hypermethylation of FHIT and poor survival was present (P = 0.0430).
CONCLUSIONS: Hypermethylation of FHIT is a frequent and early event in HCC, it might relate to a poor prognosis for patients with HCC.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16784654

Source DB:  PubMed          Journal:  Zhonghua Wai Ke Za Zhi        ISSN: 0529-5815


  3 in total

Review 1.  Tumor suppressor and hepatocellular carcinoma.

Authors:  Juliette Martin; Jean-Francois Dufour
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

Review 2.  DNA methylation in hepatocellular carcinoma.

Authors:  Iris Tischoff; Andrea Tannapfe
Journal:  World J Gastroenterol       Date:  2008-03-21       Impact factor: 5.742

3.  Association of FHIT expression and FHIT gene hypermethylation with liver cancer risk: a PRISMA-compliant meta-analysis.

Authors:  Yaping Zhang; Xiao Xu; Zhiliang Chen; Zhenhua Zhao
Journal:  Onco Targets Ther       Date:  2017-06-20       Impact factor: 4.147

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.